Pelthos Therapeutics Inc (PTHS) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Pelthos Therapeutics Inc   (NYSEAMER: PTHS)

Select the Financial Report: Select the Period:


Description of Pelthos Therapeutics Inc's Business Segments
The Company operates through two reporting segments: Commercial Operations, which includes the sale, promotion, and commercialization of approved commercial products; and Research and Development, which focuses on developing a novel class of NaV blockers targeting the peripheral nervous system, as well as activities to expand the NITRICIL nitric oxide-based technology. Segment information is disclosed based on the Company's internal organization for operating decisions and financial performance evaluation.

Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Composition of Pelthos Therapeutics Inc Revenues by Segments
 
Commercial operations    97.79 % of total Revenue
Research and Development operations    2.21 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)		 %
(of total Revenues)
Commercial operations 10.67 97.79 %
Research and Development operations 0.24 2.21 %
Total 10.91 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%		 Q/Q Revenue
%
Commercial operations - -
Research and Development operations - -
Total - -35.06 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)		 %
(Profit Margin)
Commercial operations -10.29 -
Research and Development operations 0.06 22.82 %
Total -10.24 -




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%		 Q/Q Income
%
Commercial operations - -
Research and Development operations - -
Total - -




Annual Report on Pelthos Therapeutics Inc Divisions, Sales by Country

 
Commercial operations   Commercial operations Segment contribution to total sales 96.49 % of total Revenue
Research and Development operations   Research and Development operations Segment contribution to total sales 3.51 % of total Revenue


Twelve months ended 2025
PTHS s Annual Revenue by Geography and Business Segments Sales
(in millions $)		 %
(of total Sales)
Commercial operations 16.21 96.49 %
Research and Development operations 0.59 3.51 %
Total 16.80 100 %


Twelve months ended 2025
PTHS s Annual Income by Country and Business Segments Income
(in millions $)		 %
(Profit Margin)
Commercial operations -37.26 -
Research and Development operations -6.06 -
Total -43.32 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.